Scientific Program 

Clinical Track

Opening Plenary Session:
Metabolic Syndrome and Prediabetes: Where are we in 2011?

Harmonizing the metabolic syndrome
George Alberti, UK

Metabolic syndrome and prediabetes in indigenous populations
Paul Zimmet, Australia

The dysglycemia paradigm
Hertzel Gerstein, Canada

Genetics and the metabolic syndrome
Oluf Pedersen, Denmark

Parallel Session:
The Therapeutic Potential of the Intestines

The metabolic relevance of gastrointestinal physiology
Jens Juul Holst, Denmark

Can we change metabolism by changing the gut flora?
Nathalie M. Delzenne, Belgium

Bile acid signaling and control of metabolism
Kristina Schoonjans, Switzerland

Targeting endocrine intestinal function to prevent or treat diabetes
Peter R. Flatt, N. Ireland

Parallel Session:
What have we Learned about Preventing Diabetes from Randomized Trials and Epidemiology?

Population based approaches for preventing type 2 diabetes
Jonathan Shaw, Australia

Non-pharmacological intervention for diabetes mellitus prevention in populations: Where do we stand?
Peter Schwarz, Germany

Use of PPAR-γ for therapy of prediabetes
Bernard Zinman, Canada

Microcirculatory function as a novel target in the prevention of diabetes
Coen Stehouwer, The Netherlands

Parallel Session:
Manipulating Beta Cell Biology

Beta cell biology for the clinician
Philippe Halban, Switzerland

The beta cell as the root cause of diabetes
Ele Ferrannini, Italy

How do preventive therapies affect beta cell function?
Steven Kahn, USA

How do preventive therapies affect beta cell replication and mass?
Juris J. Meier, Germany

Parallel Session:
Targeting Products of the Glucagon Gene

Glucagon - how critical is it in the pathogenesis of prediabetes and diabetes?
Pierre Lefèbvre, Belgium

Are defects in the incretin axis the early event in glucose intolerance?
Tina Vilsboll, Denmark

Non-traditional effects of the incretins
Jens Juul Holst, Denmark

L-cell peptides: A role in the prevention of diabetes?
Michael Nauck, Germany

Plenary Session:
Genetic and Epigenetic Targets for Preventing and Treating Diabetes

Can genetic markers predict incident diabetes?
Leif Groop, Sweden

The roots of the metabolic syndrome can be traced to genetics/epigenetics/environment
Claudine Junien, France

Debate/Discussion: The roots of diabetes mellitus - Genetics vs. Epigenetics

The role of genetic predisposition in type 2 diabetes development
Mark McCarthy, UK

The role of epigenetic processes in predisposition to Type 2 diabetes
Mark Hanson, UK

Parallel Session:
Circulating Cells as New Therapeutic Targets: Modulating Inflammatory and Immune Pathophysiology

What is the role of inflammation in type 2 diabetes and the metabolic syndrome?
Allison Goldfine, USA

Is there a role for immune therapy in type 2 diabetes?
Ake Lernmark, Sweden

Is there a role for adiponectin in therapy of type 2 diabetes?
Avi Karasik, Israel

Is there a role for anti-inflammatory drugs in type 2 diabetes therapy?
Marc Donath, Switzerland

Parallel Session:
Diabetes and Metabolic Syndrome: Allied Conditions

How is sleep apnea related to diabetes and the metabolic syndrome?
John Wilding, UK

Obesity classification: moving beyond BMI
Arya Sharma, Canada

Physiologic and therapeutic implications of the link between diabetes and psychiatric disease
John W. Newcomer, USA

Bone – pancreas connection: The role of Vitamin D in diabetes and the metabolic syndrome
Anastassios G. Pittas, USA

Parallel Session:
Changing the Messenger: Targeting Insulin Physiology

The pathophysiology of diabetes from the perspective of the insulin message
C. Ronald Kahn, USA

How does changing the insulin message affect the pathogenesis of diabetes?
Michael Roden, Germany

Can manipulating insulin physiology affect muscle response to fasting and exercise, in health and in diabetes?
Juleen R. Zierath, Sweden

Does manipulating insulin physiology affect ectopic fat deposition and its consequences?
Peter Arner, Sweden

Parallel Session:
Does Targeting Lipid Physiology Prevent the Consequences of Diabetes?

Therapeutic benefits of targeting HDL-raising
Philip Barter, Australia

Fibrates for the prevention of diabetes consequences
Henry Ginsberg, USA

Debate:
Statins should be prescribed to everyone with diabetes?
Yes – Naveed Sattar, UK
No – Eberhard Standl, Germany

Parallel Session:
Glucose, A1c & CV Complications

The implications of using A1c versus glucose levels: are prediabetes and diabetes obsolete terms?
Stefano Del Prato, Italy

Increased CVD in ACCORD: does glucose lowering reduce CVD?
Matthew Riddle, USA

Does reducing postprandial lipemia reduce CVD?
Jens Juul Holst, Denmark

Does glucose lowering reduce microvascular outcomes?
Mark Cooper, Australia

Parallel Session:
Novel Targets for Glycemia and Obesity Control

Speakers:
Nancy Thornburry, Merck 

New paradigms for incretin based therapy of type 2 Diabetes
Philip Larsen, USA - Lilly

Alan Moses, Novo Nordisk

Stem cells, drug discovery and diabetes: understanding challenges and opportunities
Gianni Gromo, Switzerland - Roche

Parallel Session:
Bariatric/Metabolic Surgery for Type 2 Diabetes

Moderators:
Francesco Rubino, USA
Gabriella Segal-Lieberman, Israel

• Clinical outcomes: benefits, risks and long-term survival after bariatric/metabolic
  surgery in diabetic patients
  • Efficacy and safety of metabolic surgery for the treatment of type 2 diabetes
    Philip Schauer, USA
  • Bariatric surgery, CV risk and mortality risk reduction in patients with diabetes
    Gabriella Segal-Lieberman, Israel
    
    
• PANEL: Reducing CV risk in patients with diabetes: coronary or gastric bypass?
  Paul Zimmet, Australia; George Alberti, UK; Avi Karasik, Israel
  
  
• Mechanisms of Surgical Control of Diabetes
  • GI Surgery and diabetes control: evidence for weight-independent mechanisms
    David Cummings, USA
  • Is the gut the missing link between obesity and diabetes?
    Francesco Rubino, USA
    
    
• PANEL: Metabolic surgery and the role of the gut in diabetes
  Jens Holst, Denmark; Peter R. Flatt, N. Ireland

Parallel Session: 
State of the art clinical approach to prevention of CVD in patients with prediabetes/diabetes 

Background presentation:

What do the diabetes/prediabetes cardiovascular outcome trial results say about how to manage the patient in front of you? 
Hertzel Gerstein, Canada

Debate:

Treating each component of the metabolic syndrome will reduce the risk of cardiovascular outcomes

No - Jaakko Tuomilehto, Finland

Yes - Robert Eckel, USA 

Q & A

Parallel Session:
CVD risk in diabetes throughout lifespan

Glycemic triumvirate and CVD: Is the whole more than the sum of its parts?
Louis Monnier, France

CVD risk in children and adolescents with diabetes/metabolic syndrome
Ram Weiss, Israel

CVD risk in women with diabetes: changes throughout the lifespan
Helen Colhoun, Ireland

CVD in adults with diabetes: hyperglycemia and beyond
Robert H. Eckel, USA